Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06705803 · ClinicalTrials.gov registry record
Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE)
A clinical trial of Prostate Cancer, sponsored by University of Chicago.
- Recruiting
- Registry status
- 3,000
- Enrollment target
- 2
- Study locations
NCT06705803: Recruiting study of Prostate Cancer, sponsored by University of Chicago.
NCT06705803 is a study of Prostate Cancer that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 3,000 participants, above the 604-participant average among 735 other Prostate Cancer trials with a reported enrollment target (397% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06705803, a study of Prostate Cancer, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- 3,000 participants
- Enrollment target
- 2
- Study locations
Study Summary
Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous cancer of men in the world. In 2023 alone, it is estimated that 288,300 US men will be diagnosed with prostate cancer and 34,700 will die from the disease despite the approval of multiple systemic agents. Due to advances in screening and imaging technology, PCa is now detected much earlier in its disease course. Prostate gland ablation for prostate cancer might provide the option for a "middle" ground between active surveillance (AS) and radical therapy by destroying prostate cancer in a minimally invasive or non-invasive fashion and thus limiting the morbidity. This treatment strategy is increasingly being offered to patients due to low morbidity but the data on long term oncologic efficacy and side effect profile is lacking for such a treatment strategy. The purpose of this study is to create a database and prospective registry for data collection on patients with prostate cancer undergoing prostate ablation for the management of prostate cancer. Patients with biopsy-proven prostate cancer of any Gleason Grade will be entered into the registry as long as prostate ablation is used as the prostate cancer management modality. Historical data from 2017 to the present time will be added through chart review. Current and future patient data will be collected through chart review during the subject's clinical care. Only data available in the electronic medical record will be collected and no additional data will be collected for research purposes. No biospecimens will be collected, and there are no physical risks from study participation.
Conditions Studied
Interventions
- PROCEDURE Prostate Ablation
Study Locations (2)
Illinois
- The University of Chicago - Hyde Park
Ohio
- The University of Cinncinatti - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2024-06-21 |
| Est. Completion | 2029-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06705803
The ClinicalTrials.gov registry entry for NCT06705803 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 3,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 604-participant average among 735 other Prostate Cancer trials with a reported enrollment target (397% higher). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Prostate Ablation is the first listed.
NCT06705803 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Ohio.
Frequently Asked Questions
What is clinical trial NCT06705803 about?
NCT06705803 is a clinical study titled "Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE)". Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous cancer of men in the world. In 2023 alone, it is estimated that 288,300 US men will be diagnosed with prostate cancer and 34,700 will die from the disease despite the approval of multiple systemic agents. Due to advances in screening...
What is the current status of trial NCT06705803?
This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2024-06-21. Estimated completion is 2029-06.
What conditions does trial NCT06705803 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT06705803?
The interventions under investigation include: Prostate Ablation (PROCEDURE).
Who is sponsoring clinical trial NCT06705803?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06705803 being conducted?
This trial has 2 study locations across Illinois, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.